Qualigen Therapeutics Advances $1.25 Million to Marizyme via Promissory Note at 18% Interest

AIxCrypto Holdings, Inc.

Qualigen advanced $1,250,000 to Marizyme, Inc. on July 15, 2024, under a demand promissory note dated July 12, 2024.
The note bears interest at 18% per annum and allows prepayment without premium or penalty.
The agreement is disclosed under Item 1.01 of Form 8-K filed July 18, 2024, signed by CEO Michael S. Poirier.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.